Latent Toxoplasmosis in Females With Borderline Personality Disorder

Marie Ociskova

Status: Withdrawn

Conditions: Borderline Personality Disorder; Toxoplasmosis

Treatments: Behavioral: Combined schema-therapy and cognitive behavioral therapy; Drug: Psychopharmaceuticals

Study type: Observational

Funder types: Other

Identifiers

NCT03932656

NV19-05-00105

Details and patient eligibility

About

Borderline personality disorder is a common mental disorder with core features of affective dysregulation, impulsivity, and identity disturbance. Although this disorder is mostly understood as a result of a combination of biological factors (genes, temperament) and early aversive experiences (often of traumatic nature), recent data suggest that other factors may be important in its development and course. Preliminary findings show that patients with borderline personality disorder have higher prevalence of Toxoplasma seropositivity. This infection may manifest in symptoms such as affective dysregulation, aggression, suicidality, or anxiousness. As such, it may play a role in the psychopathology of the borderline personality disorder. The aim of this study is to explore the prevalence of Toxoplasma seropositivity in a sample of females with borderline personality disorder, its clinical correlates, and a potential impact on outcomes of an intensive six-week inpatient schema-therapeutic treatment. Results may enrich our understanding of this disorder and lead to improvements of the therapeutic approaches.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult
• Female
• Borderline personality disorder diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders-5 criteria
• Signed informed consent

Exclusion criteria

• Current substance abuse disorder
• Psychotic disorder, bipolar disorder, organic mental disorder current or past
• Severe suicidal risk
• Severe somatic illness (e.g., endocrinopathy, oncologic, hematologic, cardiologic, or neurologic illness)

Trial design

0 participants in 1 patient group

Females with borderline personality disorder

Treatment:

Behavioral: Combined schema-therapy and cognitive behavioral therapy

Drug: Psychopharmaceuticals